702 Results

People

  1. Motzer
    Motzer
  2. Livingston
    Livingston
  3. Norton
    Norton
  4. Aghajanian
    Aghajanian
  5. Hudis
    Hudis
  6. Krown
    Krown
  7. Sepkowitz
    Sepkowitz
  8. O'Reilly
    O'Reilly
  9. Panageas
    Panageas
  10. Horwitz
    Horwitz

Groups

  1. Department of Medicine (450)
  2. Solid Tumor Oncology Division (259)
  3. Hematologic Malignancies, Division of (178)
  4. Center for Hematologic Malignancies (151)
  5. Surgery (92)
  6. Survivorship Research (88)
  7. Epidemiology and Biostatistics (73)
  8. GSK Faculty (73)
  9. Division of Subspecialty Medicine (65)
  10. Gastrointestinal Oncology Service (64)
  1. "fever"
Formats
  1. Journal Article (657)
  2. Review (23)
  3. Conference Paper (6)
  4. Research Letter (6)
  5. Guidelines (5)
  6. Editorial (4)
  7. Correspondence (1)
Groups
  1. Department of Medicine (450)
  2. Solid Tumor Oncology Division (259)
  3. Hematologic Malignancies, Division of (178)
  4. Center for Hematologic Malignancies (151)
  5. Surgery (92)
  6. Survivorship Research (88)

More Groups

People
  1. Robert Motzer (24)
  2. Larry Norton (20)
  3. Philip Livingston (19)
  4. Carol Aghajanian (17)
  5. Clifford Hudis (17)
  6. Kent Sepkowitz (17)

More People

Years
  1. 2025 (21)
  2. 2024 (42)
  3. 2023 (40)
  4. 2022 (22)
  5. 2021 (25)
  6. 2020 (44)

More Years

Publications
  1. Journal of Clinical Oncology (68)
  2. Clinical Cancer Research (33)
  3. Blood (22)
  4. Lancet Oncology (22)
  5. Cancer (21)
  6. New England Journal of Medicine (18)

More Publications

Publishers
  1. Elsevier Inc. (107)
  2. American Society of Clinical Oncology (70)
  3. Elsevier Science, Inc. (55)
  4. Springer (53)
  5. Nature Publishing Group (40)
  6. Wiley Blackwell (38)

More Publishers

Results (702)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two open-label, non-comparative, randomised, phase 2 trials
    Journal Article

    D'Angelo, S. P.; Mahoney, M. R.; Van Tine, B. A.; Atkins, J.; Milhem, M. M.; Jahagirdar, B. N.; Antonescu, C. R.; Horvath, E.; Tap, W. D.; Schwartz, G. K.; more...
    Lancet Oncology (2018)

    Fulltext@MSK | Save
  • Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
    Journal Article

    Topp, M. S.; Stelljes, M.; Zugmaier, G.; Barnette, P.; Heffner, L. T. Jr; Trippett, T.; Duell, J.; Bargou, R. C.; Holland, C.; Benjamin, J. E.; more...
    Leukemia (2018)

    Fulltext@MSK | Save
  • Cytokine release syndrome after radiation therapy: Case report and review of the literature
    Journal Article

    Barker, C. A.; Kim, S. K.; Budhu, S.; Matsoukas, K.; Daniyan, A. F.; D'Angelo, S. P.
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save
  • Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
    Journal Article

    Horwitz, S. M.; Koch, R.; Porcu, P.; Oki, Y.; Moskowitz, A.; Perez, M.; Myskowski, P.; Officer, A.; Jaffe, J. D.; Morrow, S. N.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies
    Journal Article

    Flinn, I. W.; O’Brien, S.; Kahl, B.; Patel, M.; Oki, Y.; Foss, F. F.; Porcu, P.; Jones, J.; Burger, J. A.; Jain, N.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma
    Journal Article

    Connors, J. M.; Jurczak, W.; Straus, D. J.; Ansell, S. M.; Kim, W. S.; Gallamini, A.; Younes, A.; Alekseev, S.; Illés, Á.; Picardi, M.; more...
    New England Journal of Medicine (2018)

    Fulltext@MSK | Save
  • Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses
    Journal Article

    Burke, P. W.; Aldoss, I.; Lunning, M. A.; Devlin, S. M.; Tallman, M. S.; Pullarkat, V.; Mohrbacher, A. M.; Douer, D.
    Leukemia Research (2018)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab in patients with advanced melanoma: Updated survival, response, and safety data in a phase I dose-escalation study
    Journal Article

    Callahan, M. K.; Kluger, H.; Postow, M. A.; Segal, N. H.; Lesokhin, A.; Atkins, M. B.; Kirkwood, J. M.; Krishnan, S.; Bhore, R.; Horak, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia
    Journal Article

    Stein, E. M.; Walter, R. B.; Erba, H. P.; Fathi, A. T.; Advani, A. S.; Lancet, J. E.; Ravandi, F.; Kovacsovics, T.; DeAngelo, D. J.; Bixby, D.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma
    Journal Article

    Algazi, A. P.; Esteve-Puig, R.; Nosrati, A.; Hinds, B.; Hobbs-Muthukumar, A.; Nandoskar, P.; Ortiz-Urda, S.; Chapman, P. B.; Daud, A.
    Pigment Cell & Melanoma Research (2018)

    Fulltext@MSK | Save